Vaccines and Global Health : The Week in Review 25 February 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: vaccines-and-global-health_the-week-in-review_25-february-2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives

Reaching everyone, everywhere with life-saving vaccines
Commentary
25 February 2017
Dr Margaret Chan, Director-General of WHO,
Chris Elias, President of the Global Development Program at the Bill & Melinda Gates Foundation,
Anthony Fauci, Director of the US National Institute of Allergies and Infectious Diseases,
Anthony Lake, Executive Director of UNICEF,
Seth Berkley, Chief Executive Officer of Gavi, the Vaccine Alliance

In 2015, world leaders agreed to a new development plan—a set of Sustainable Development Goals (SDGs). Expanding access to immunisation is crucial to achieving the SDGs.1, 2 Not only do vaccinations prevent the suffering and death associated with infectious diseases such as pneumonia, diarrhoea, whooping cough, measles, and polio, they also help enable national priorities like education and economic development to take hold.

The unique value of vaccines was the driving force behind the Decade of Vaccines, an effort launched at the 2010 World Economic Forum and supported by many stakeholders to extend the full benefits of immunisation to all by 2020.3 Governments welcomed the initiative, and 194 member states endorsed the Global Vaccine Action Plan (GVAP) at the 65th World Health Assembly.4 The plan is ambitious and aims to ensure that all people everywhere live free from vaccine-preventable diseases.

Since then, WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization has issued annual progress reports. The 2016 GVAP midterm report5 provides a careful analysis of progress and challenges, and indicates that although there are bright spots in global immunisation efforts, the overall picture is sobering.

First, the bright spots. More children are being immunized worldwide than ever before with the highest level of routine coverage in history (as measured by coverage of three doses of the diphtheria-tetanus-pertussis (DTP)-containing vaccine).5 The world is closer than ever to eradicating polio. Since 2010, 99 low-income and middle-income countries have introduced one or more new or underused vaccines—for example, rotavirus and pneumococcal vaccines—exceeding the GVAP target for 2015.5 Indigenous measles and rubella have been eliminated from the Americas, and maternal and neonatal tetanus has been eliminated in southeast Asia.

Important progress has been made in vaccine research and development: a new vaccine against dengue has been licensed in several countries,5 and the first vaccine to protect children against malaria will be piloted in three African countries in 2018.7 In the past 2 years, there has been an increase in the number of vaccines in the clinical development pipeline.

The GVAP midterm report also reveals encouraging national and regional trends in vaccine coverage. For example, since 2010, 16 countries have substantially increased coverage of the third dose of the DTP vaccine, confirming that progress on immunization can be achieved with strong domestic leadership, meaningful investments, and effective accountability mechanisms.
Yet major challenges remain. All of the GVAP targets for disease elimination—including measles, rubella, and maternal and neonatal tetanus—are behind schedule. Although more infants than ever before are receiving the critical third dose of the DTP vaccine, global coverage of these basic vaccines has increased by only 1% since 2010.5 This slow progress puts one of the most important goals in the GVAP seriously off track.

Although inequalities in the implementation of vaccination programmes have narrowed in the past decade as the poorest and least educated people gained more coverage, gaps persist. Only 52 of 112 member states with available and valid district-level data have surpassed the district-level coverage target of 80%. A high priority must be placed on the equitable extension of vaccine coverage to all. Finally, while financial support and commitment from donors and countries has increased, reflecting a global commitment to immunization, this increase is insufficient to meet all the needs to realize the GVAP targets.

In almost every country, some population groups have limited access to vaccines. These groups include people living in poverty, those who live in remote rural locations, segments of the urban poor, and displaced and nomadic people. This problem is compounded by data deficiencies at the national and local levels, which makes it even more challenging to identify where gaps lie and what is causing them—and thus to take corrective action. Several countries also report that vaccine prices are a barrier to the introduction of vaccines into their national programmes.

Many health facilities still have insufficient resources to engage with communities and provide them with the comprehensive public health services they need. Failure to integrate service delivery mechanisms has decreased the opportunities for health workers to improve immunization coverage and other key interventions to improve people’s health. Conflict and public health emergencies, such as the outbreaks of Ebola virus disease and Zika virus, and outbreaks of vaccine-preventable diseases—for example, measles, yellow fever, and cholera—have strained fragile health systems.

Finally, inadequate domestic investments and continued donor dependency in many low-income and middle-income countries are raising concerns about the long-term global sustainability of immunization programmes, especially as funding for the polio programme slows down and countries transition away from the support they receive from Gavi, the Vaccine Alliance.
Where do we go from here? First, the global health community must continue working to provide all vaccines recommended by WHO to each and every child by ramping up efforts to extend full immunization to the about 19 million children who are still not fully protected against a core set of vaccine-preventable diseases. Efforts to build strong routine immunization systems, which balance supply and demand, must be intensified.

Routine immunization is a building block of strong primary health care and universal health coverage—it provides a point of contact for health care at the beginning of life and offers every child the chance of a healthy life from the start. Immunization is a cornerstone of global health security in an interconnected world where diseases do not respect national borders. Vaccines also serve as a frontline defense against antimicrobial resistance. Furthermore, a 2016 study showed that for every US dollar spent on childhood vaccinations, the return on investment is US$44 when the full range of economic benefits are considered—making immunization one of the most cost-effective health interventions.

In addition to implementation challenges, we still face substantial research challenges. Vaccines are lacking or sub-optimal for many serious infectious diseases that exact an enormous toll worldwide. To address this problem, it will be crucial to ensure that vaccine markets provide the right incentives to invest in research and development for these vaccines and to expand research and development capacity in low-income and middle-income countries.

The global health community must work together to advance progress. Although governments are the main providers of immunization, the GVAP’s success depends upon many stakeholders—families, communities, health professionals, civil society, development partners, global agencies, manufacturers, media, and the private sector. It is essential that governments show strong leadership and good governance of national immunization programmes, which involves prioritizing system strengthening, securing investments, and improving surveillance capacity and data quality and use. Organisations that deliver immunization programmes, research and development partners, as well as global agencies can help improve GVAP accountability, work to overcome barriers to the timely delivery of vaccines in humanitarian crisis, and support vaccine research and development in low-income and middle-income countries.

Delivering on the goals and the promise of the GVAP is an urgent and essential priority. It will improve the health and wellbeing of people everywhere and help us achieve the SDGs, and ultimately a world in which no one—no child, no adolescent, no adult—is left behind. In 2017, we challenge countries and our own organisations to do more.

[Link to The Lancet version: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30554-8/fulltext?rss=yes ]

Emergencies

Emergencies

WHO Grade 3 Emergencies [to 25 February 2017]
Iraq
Read the health situation report from Mosul pdf, 521kb 18 February 2016

Nigeria
Statement on Nigeria and the Lake Chad Region in Oslo Humanitarian Conference
24 February 2017 Oslo, Norway
As several speakers have noted today, while there are enormous food security, nutrition and protection dimensions to the crisis in the Lake Chad Region, this is also a public health crisis, with rates of death, malnutrition and disease rarely seen over the past 20 years.
In Nigeria and the Lake Chad Region, lack of qualified health workers, essential medicines and the destruction of medical facilities hamper the delivery of lifesaving health care. Widespread food insecurity and malnutrition are associated with severe health consequences. As you know, malnutrition lowers the body’s capacity to fight infection – a malnourished child is far more prone to contract an infectious disease such as pneumonia, diarrhoea and measles – and then to die from that disease. As one of our local staff in Niger said to me once – between malnutrition and death, there is always disease.
All four countries in the Lake Chad Region have similar health priorities: rapidly expanding access to a package of essential health care – including child and reproductive health; boosting immunization rates; preventing, detecting and responding to disease outbreaks; effectively treating malnutrition and its consequences. We also must address psychosocial problems, sexual and gender-based violence, and violent trauma leading to physical injuries. Together, health sector partners seek to help 8.2 million people this year…

South Sudan
South Sudan: Amidst insecurity, WHO in collaboration with the Ministry of Health and partners intensifies the health response to the cholera outbreak
14 February 2017, Juba, South Sudan – Despite the ongoing complex humanitarian crises in South Sudan, the World Health Organization (WHO) in partnership with the Ministry of Health and partners are responding to the latest cholera outbreak in the former Jonglei and Lakes States. The outbreak of cholera was first detected in June 2016 and since then 5 006 cholera cases and 99 deaths (CFR 1.98%) have been reported from 12 Counties in nine states countrywide.

Yemen
Yemeni health system crumbles as millions risk malnutrition and diseases
23 February 2017, Al-Hudaydah, Yemen – “Hospital staff have not received their salaries for the past 5 months. There are acute shortages of certain medicines and we need more fuel to ensure the hospital has electricity,” says Dr Khaled Suhail, Director of Al-Tharwa Hospital in Yemen’s third largest city, Al-Hudaydah. With more than 1200 employees and 320 beds, Al-Thawra Hospital is the main functioning health facility in Al-Hudaydah and neighbouring governorates.

The Syrian Arab RepublicNo new announcements identified

::::::
::::::

WHO Grade 2 Emergencies [to 25 February 2017]
Cameroon No new announcements identified.
Central African Republic No new announcements identified.
Democratic Republic of the CongoNo new announcements identified.
EthiopiaNo new announcements identified.
LibyaNo new announcements identified.
MyanmarNo new announcements identified.
NigerNo new announcements identified.
UkraineNo new announcements identified.

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 

Iraq
:: Iraq: Mosul Humanitarian Response Situation Report No. 21 (13 February – 19 February 2017)

Syria
:: Statement to the Security Council on Syria 22 Feb 2017
:: 24 Feb 2017
Health Resources Availability Mapping System (HeRAMS) Report – Turkey Hub Health Cluster for Syria, 2016

Yemen
:: Escalating Conflict on Yemen’s Western Coast – Flash Update # 2 | 25 February 2017
:: 21 Feb 2017
Statement by the Humanitarian Coordinator in Yemen, Jamie McGoldrick, on the Impact of the Conflict and Ongoing Food Crisis [EN/AR]

::::::

UNICEF [to 25 February 2017]
https://www.unicef.org/media/media_94367.html
21 February 2017
Nearly 1.4 million children at imminent risk of death as famine looms in Nigeria, Somalia, South Sudan and Yemen – UNICEF
NEW YORK/DAKAR/NAIROBI/AMMAN,– Almost 1.4 million children are at imminent risk of death from severe acute malnutrition this year, as famine looms in Nigeria, Somalia, South Sudan and Yemen, UNICEF said today.

WHO: Rapid response teams and medicines deployed to cholera outbreak in South Sudan
February 2017 – Essential medicines and supplies have been delivered to communities in South Sudan affected by the cholera outbreak. The supplies were deployed along with rapid response teams that are currently working alongside local teams to control the outbreaks.
[No mention of OCV use]

WHO: About 17 million people are affected by crisis in the Lake Chad Basin
23 February 2017 – Years of violent conflict have deprived millions of people in north-eastern Nigeria, northern Cameroon, western Chad and south-east Niger of even the most basic health care services. Malnutrition is widespread and in the 3 worst-affected states of Nigeria nearly 6 million men, women, children and infants urgently need health assistance. WHO is working with the Nigerian Ministry of Health and partners to reach those in need with lifesaving health care.
…Millions of people in Borno State have had limited or no access to regular health services over a number of years, leading to very low vaccination rates. The ongoing movement of internally displaced people also makes it difficult to track those who have or have not been immunized. WHO supported a measles vaccination campaign in January 2017 which reached nearly 3 million children. Polio is still endemic in Nigeria, but WHO and its partners have vaccinated over 1.8 million children under five against the disease in a continued effort to eradicate it…

PAHO -Epidemiological Alerts and Updates
:: 24 February 2017: Cholera – Epidemiological Update
Between epidemiological week (EW) 1 and 5 of 2017, a total of 1,897 cholera cases were reported in Haiti, including 28 deaths. In the Dominican Republic, from the beginning of the year to EW 2 of 2017, there were 7 suspected cholera cases and 2 confirmed cases reported, including one death.

::::::
::::::

POLIO [to 25 February 2017]
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 15 February 2017
Country Updates [Selected Excerpts]
Afghanistan
:: One new wild poliovirus type 1 (WPV1) case was reported in the past week from Nahr-e-Saraj district, Helmand province, with onset of paralysis on 21 January. The total number of WPV1 cases for 2016 remains 13, and two for 2017.
:: One new environmental WPV1 positive sample was reported in the past week from Jalalabad, Nangarhar, collected on 24 January
Pakistan
:: One new wild poliovirus type 1 (WPV1) case was reported in the past week from Lodhran district, Punjab province, with onset of paralysis on 28 January 2017. This is the first case in Punjab since December 2015, and an immunization response is already being implemented.
:: One new environmental WPV1 positive sample was reported in the past week, from Quetta, Balochistan, collected on 20 January.

::::::

Japan gives US$ 33.3 million in emergency polio funding
17/02/2017
New funding will contribute to emergency efforts in Nigeria and Lake Chad Region to prevent further spread of polio and stop the outbreak for good
US$ 33.3 million grant from the Government of Japan in humanitarian emergency funding to UNICEF was announced this week and will help to protect millions of children from polio in Nigeria and the Lake Chad region.
In response to the urgent need to rapidly raise immunity to polio virus in the region, Japan has generously provided exceptional funding from their supplementary budget envelope to purchase polio vaccines, conduct house-to-house polio campaigns and support communication efforts to mobilize communities for vaccination in Nigeria, Chad, Niger, Cameroon and the Central African Republic…

::::::
::::::

Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

Zika virus [to 25 February 2017]
http://www.who.int/emergencies/zika-virus/en/
Latest Report [apparently no longer bi-weekly]:
Zika situation report – 2 February 2017
Full report: http://apps.who.int/iris/bitstream/10665/254507/1/zikasitrep2Feb17-eng.pdf?ua=1
Analysis
Overall, the global risk assessment has not changed. Zika virus continues to spread geographically to areas where competent vectors are present. Although a decline in cases of Zika infection has been reported in some countries, or in some parts of countries, vigilance needs to remain high.
[See PAHO announcements below]

Yellow Fever [to 25 February 2017]
http://www.who.int/emergencies/yellow-fever/en/
Disease Outbreak News (DONs)
:: Yellow fever – Brazil 24 February 2017 –
From 1 December 2016 to 22 February 2017, a total of 1336 cases of yellow fever infection (292 confirmed, 920 suspected, and 124 discarded), including 215 deaths (101 confirmed, 109 suspected, 5 discarded), have been detected in six states (Bahia, Espírito Santo, Minas Gerais, Rio Grande do Norte, São Paulo, and Tocantins). The estimated case fatality rate is 35% for confirmed cases and 12% for suspected cases. To date, the majority (86%) of the confirmed cases are men and of which, approximately 81% are aged between 21 and 60 years.

EBOLA/EVD [to 25 February 2017]
http://www.who.int/ebola/en/
No new digest content identified for this edition.

MERS-CoV [to 25 February 2017]
http://www.who.int/emergencies/mers-cov/en/
No new digest content identified for this edition.

WHO: Disease Outbreak News (DONs)
:: 24 February 2017 – Yellow fever – Brazil
:: 23 February 2017 – Meningococcal disease – Togo
:: 22 February 2017 – Human infection with avian influenza A(H7N9) virus – China
:: 20 February 2017 – Seoul virus – United States of America and Canada
:: 20 February 2017 – Human infection with avian influenza A(H7N9) virus – China

WHO & Regional Offices [to 25 February 2017]

WHO & Regional Offices [to 25 February 2017]

Reducing maternal and newborn deaths by half
14 February 2017 – Today, 9 countries – Bangladesh, Cote d’Ivoire, Ethiopia, Ghana, India, Malawi, Nigeria, Tanzania and Uganda – committed to halving preventable deaths of pregnant women and newborns in their health facilities within the next 5 years. Through a new network supported by WHO, UNICEF, and other partners, these countries will improve the quality of care mothers and babies receive.

Highlights
Rapid response teams and medicines deployed to cholera outbreak in South Sudan
February 2017 – Essential medicines and supplies have been delivered to communities in South Sudan affected by the cholera outbreak. The supplies were deployed along with rapid response teams that are currently working alongside local teams to control the outbreaks.

WHO issues first viral hepatitis testing guidelines
February 2017 – WHO issued its first-ever global guidance on testing for chronic viral hepatitis B and C on 16 February 2017. Viral hepatitis causes an estimated 1.4 million deaths worldwide each year. he guidelines were released in a special session at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), held in Shanghai, China.

South African government commits to implement sugary drinks tax to tackle diabetes and obesity
February 2017 – WHO strongly supports announcement by the Government of South Africa to implement a tax on sugary beverages as part of the country’s campaign to promote the health of its citizens and combat the increasing challenges of diabetes and obesity.

Sri Lanka gears up to host Global Consultation on Migrant Health
February 2017 – Health leaders will gather in Colombo, from 21 to 23 February 2017, for a landmark consultation on migrant health. The 2nd Global Consultation on Migrant Health, jointly organized by the Government of Sri Lanka, IOM and WHO, strives to build international solidarity to enhance the health and well-being of migrants and their families.

Weekly Epidemiological Record, 24 February 2017, vol. 92, 8 (pp. 89–96)
Continued endemic wild poliovirus transmission in security-compromised areas – Nigeria, 2016

::::::

:: WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: About 17 million people are affected by crisis in the Lake Chad Basin 23 February 2017
:: WHO and the African Union Commission map the way forward for stronger partnership – 18 February 2017
:: Gavi, the Vaccine Alliance visits the WHO Regional Office for Africa – 18 February 2017

WHO Region of the Americas PAHO
:: WHO and PAHO Initiative to Support 17 New Research Proposals on Zika in Seven Countries in Latin America and the Caribbean (02/23/2017)
:: Early cancer diagnosis saves lives, cuts treatment costs (02/03/2017)
:: The Zika Virus outbreak continues one year after the global emergency (02/02/2017)
:: Overweight affects almost half the population of all countries in Latin America and the Caribbean except for Haiti (01/18/2017)

WHO South-East Asia Region SEARO
:: Migrant Health: Resetting the agenda
21 February 2017 – The health problems of refugees and migrants are similar to those of the rest of the population. The most frequent health problems of newly arrived refugees and migrants include accidental injuries, hypothermia, burns, cardiovascular events, pregnancy and delivery-related complications, diabetes, and hypertension. Key stakeholders are discussing improving the health aspects of refugees and migrants, in the 2nd Global Consultation on Migrant Health, on 21–23 February 2017, in Colombo, Sri Lanka.

WHO European Region EURO
:: The Crown Princess of Denmark, WHO/Europe Patron, receives WHO Medal for commendable contributions to global health 24-02-2017
:: Tobacco control activities in Turkey enter a new phase, with leaders looking to ensure sustainability 24-02-2017
:: Slovenian National Assembly passes strong tobacco control law 20-02-2017

WHO Eastern Mediterranean Region EMRO
:: Tracing every last virus:  Afghanistan steps up surveillance to accelerate polio eradication
Kabul 23 February 2017 – Afghanistan’s strong surveillance system is the backbone of the country’s polio eradication effort. It ensures that every single poliovirus is detected and analysed, enabling a quick and effective response to stop every strain of the debilitating virus. Afghanistan is closer than ever to stopping polio. Together with partners of the Global Polio Eradication Initiative, WHO is further strengthening Afghanistan’s surveillance system to accelerate progress towards a polio-free Afghanistan.

WHO Western Pacific Region
:: A new vision for WHO–Lao People’s Democratic Republic partnership
VIENTIANE CAPITAL, 21 February 2017 – Over the past decade, the Lao People’s Democratic Republic has observed significant improvements in the health status of the population. People are living longer, maternal mortality and deaths from malaria have been drastically reduced, and the number of tuberculosis cases is in decline. However, these impressive improvements in the country’s health are at risk from a new set of challenges, including rapidly increasing rates of noncommunicable disease and injury.

CDC/ACIP [to 25 February 2017]

CDC/ACIP [to 25 February 2017]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/

MMWR Weekly February 24, 2017 / No. 7
[Excerpts]
:: Near Real-Time Surveillance of U.S. Norovirus Outbreaks by the Norovirus Sentinel Testing and Tracking Network — United States, August 2009–July 2015
:: Continued Endemic Wild Poliovirus Transmission in Security-Compromised Areas — Nigeria, 2016

Gavi [to 25 February 2017]

Gavi [to 25 February 2017]
http://www.gavi.org/library/news/press-releases/
23 February 2017

Gavi seeks to support innovative solutions to improve vaccine delivery
To propose cutting edge technology that could save lives, apply to INFUSE 2017
Geneva, 23 February 2017 – To ensure vaccines reach all the world’s children, Gavi is inviting entrepreneurs and businesses to identify innovations in vaccine delivery by applying to its INFUSE initiative.
With global immunisation coverage stalled at around 80% for several years and 19 million children missing out on a full course of basic vaccines, Gavi launched INFUSE – Innovation for Uptake, Scale and Equity in Immunisation – in 2016. This aims to find new thinking and technology that will help modernise often outdated vaccine delivery systems and then accelerate the expansion of these solutions.
“The speed with which the disease outbreaks disrupt the lives of children in the world’s poorest countries is only getting faster. We need to keep up and find new innovative solutions to evolving challenges and gaps in immunisation coverage which affect the most vulnerable children”, said Managing Director of resource mobilisation and private sector partnerships Marie-Ange Saraka-Yao.
“To create these solutions, we started INFUSE. This platform brings together global problem solvers who can find new ways to accelerate immunisation coverage and reduce inequities in access to vaccination for the world’s poorest children.”
Following last year’s launch at the World Economic Forum Annual Meeting in Davos, Gavi has already helped one of INFUSE’s initial pacesetters, Nexleaf Analytics, forge a partnership with Google.org. Together these two companies are working to provide real-time data solutions to keep vaccines cold and safe in developing countries…

NIH [to 25 February 2017]

NIH [to 25 February 2017]
http://www.nih.gov/news-events/news-releases
February 22, 2017

Respiratory syncytial virus vaccine enters clinical testing
NIH-led trial to evaluate RSV vaccine’s safety in healthy adults.
A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial also will assess the vaccine’s ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH…

.

Rare Disease Day at NIH event features advances in rare diseases research
February 22, 2017 — Rare diseases affect an estimated 25 million Americans.

.

NIH begins study of vaccine to protect against mosquito-borne diseases
February 21, 2017 — Experimental vaccine targets mosquito saliva.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. The study, which is being conducted at the NIH Clinical Center in Bethesda, Maryland, will examine the experimental vaccine’s safety and ability to generate an immune response.
The investigational vaccine, called AGS-v, was developed by the London-based pharmaceutical company SEEK, which has since formed a joint venture with hVIVO in London. The consulting group Halloran has provided regulatory advice to both companies.
Unlike other vaccines targeting specific mosquito-borne diseases, the AGS-v candidate is designed to trigger an immune response to mosquito saliva rather than to a specific virus or parasite carried by mosquitoes. The test vaccine contains four synthetic proteins from mosquito salivary glands. The proteins are designed to induce antibodies in a vaccinated individual and to cause a modified allergic response that can prevent infection when a person is bitten by a disease-carrying mosquito…

.

Experimental PfSPZ malaria vaccine provides durable protection against multiple strains in NIH clinical trial
February 21, 2017 — An investigational malaria vaccine has protected a small number of healthy U.S. adults from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy of Sciences (PNAS). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and co-conducted the Phase 1 clinical trial.
… The PfSPZ Vaccine used in this study was developed by Sanaria Inc., of Rockville, Maryland. The vaccine contains weakened P. falciparum sporozoites that do not cause infection but are able to generate a protective immune response against live malaria infection. Earlier research at the NIH Clinical Center with the PfSPZ Vaccine found it to be safe, well-tolerated and protective for more than a year when tested in healthy U.S. adults against a single Africa-derived malaria strain matched to the PfSPZ Vaccine.
“An effective malaria vaccine will need to protect people living in endemic areas against multiple strains of the mosquito-borne disease,” said NIAID Director Anthony S. Fauci, M.D. “These new findings showing cross-protection with the PfSPZ Vaccine suggest that it may be able to accomplish this goal.”…

UNAIDS [to 25 February 2017]

UNAIDS [to 25 February 2017]
http://www.unaids.org/

Update
Italy invests half a million euros to support UNAIDS’ work in Ethiopia
21 February 2017
The Italian Government signed on 21 February a financing agreement for €500 000 to support UNAIDS’ efforts to end the AIDS epidemic in Ethiopia. The funds will be invested in a special project to bolster UNAIDS’ work in improving community health education and capacity- and knowledge-building. The project will be implemented across 10 areas of the Southern Nations, Nationalities and Peoples’ Region of the country over a 12-month period…

Update
CROI shows the importance of 90–90–90
21 February 2017
A number of important updates were announced at the annual Conference on Retroviruses and Opportunistic Infections (CROI) that have shown the importance of, and ways to achieve, the 90–90–90 targets, whereby, by 2020, 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing treatment and 90% of people on treatment have suppressed viral loads.
Held in Seattle, United States of America, from 13 to 16 February, CROI, the foremost annual scientific research conference on HIV, brought together around 4000 scientists, researchers, clinicians, students and others working in the response to HIV and related diseases…

Industry Watch

Industry Watch

:: In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
February 24, 2017 04:00 PM Eastern Standard Time
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients. This was a double-blind, randomized, placebo-controlled, multi-center trial to study safety, tolerability, efficacy and immunogenicity of inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Stem Cell Transplants (auto-HSCT). In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent (95% CI, 0.48, 0.75) in recipients of auto-HSCT. These results were presented today, as an oral presentation, at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) during a “Best Abstracts” session in Orlando, Florida…

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders
Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Immunization Financing: A Resource Guide for Advocates, Policymakers, and Program Managers
Results for Development, Washington, DC
2017 :: 128 pages
PDF: http://immunizationfinancing.org/home/Immunization_Financing_Resource_Guide_2017_FULL.pdf
Preface
This resource guide collects 26 brief documents on topics related to the cost and financing of national immunization programs in low- and middle-income countries. Some of the briefs explore possible financing sources. Others examine the components and drivers of immunization costs, planning and decision-making processes related to immunization programs and budgets, and the relationship between immunization and broader health system financing. The resource guide concludes with a set of country case studies that illustrate particular approaches or important challenges.

This volume is intended for immunization advocates, program managers, decision-makers, and planners in ministries of health and finance. The information is relevant to countries that are eligible for support from Gavi, the Vaccine Alliance, as well as to countries that are transitioning out of Gavi support and middle-income countries that have never received Gavi support.

The briefs can be read in sequential order or individually. Each begins with a summary of key
points. Some of the briefs are more technical than others, due to their subject matter, but they are all meant to convey practical information to readers who do not have specific technical expertise. Many of the briefs recommend other resources that offer more in-depth information.

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Hepatitis C virus and HIV co-infection among pregnant women in Rwanda

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 25 February 2017)

Research article
Hepatitis C virus and HIV co-infection among pregnant women in Rwanda
Hepatitis C virus (HCV) infection is a pandemic causing disease; more than 185 million people are infected worldwide. An HCV antibody (Ab) prevalence of 6.0% was estimated in Central African countries. The study aimed at providing HCV prevalence estimates among pregnant women in Rwanda.
Mwumvaneza Mutagoma, Helene Balisanga, Dieudonné Sebuhoro, Aimable Mbituyumuremyi, Eric Remera, Samuel S. Malamba, David J. Riedel and Sabin Nsanzimana
BMC Infectious Diseases 2017 17:167
Published on: 22 February 2017
2017

A longitudinal study on determinants of HPV vaccination uptake in parents/guardians from different ethnic backgrounds in Amsterdam, the Netherlands

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 25 February 2017)

Research article
A longitudinal study on determinants of HPV vaccination uptake in parents/guardians from different ethnic backgrounds in Amsterdam, the Netherlands
Human papillomavirus (HPV) vaccination coverage in the Netherlands is low (~60%) compared to other childhood vaccinations (>90%), and even lower among ethnic minorities. The aim of this study was to explore th…
Catharina J. Alberts, Maarten F. Schim van der Loeff, Yvonne Hazeveld, Hester E. de Melker, Marcel F. van der Wal, Astrid Nielen, Fatima El Fakiri, Maria Prins and Theo G. W. M. Paulussen
BMC Public Health 2017 17:220
Published on: 21 February 2017

Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE- Palestine

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 25 February 2017]

Short report
Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE- Palestine
Little has been written on the challenges of conducting research in regions or countries with chronic conflict and strife. In this paper we share our experiences in conducting a population based study of chron…
Rasha Khatib, Rita Giacaman, Umaiyeh Khammash and Salim Yusuf
Conflict and Health 2017 10:33
Published on: 22 February 2017

Corporate social responsibility to improve access to medicines: the case of Brazil

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 25 February 2017]

Research
Corporate social responsibility to improve access to medicines: the case of Brazil
Halla Thorsteinsdóttir, Natasha Ovtcharenko and Jillian Clare Kohler
Published on: 21 February 2017
Abstract
Background
Access to medicines and the development of a strong national pharmaceutical industry are two longstanding pillars of health policy in Brazil. This is reflected in a clear emphasis by Brazil’s Federal Government on improving access to medicine in national health plans and industrial policies aimed at promoting domestic pharmaceutical development. This research proposes that such policies may act as incentives for companies to pursue a strategic Corporate Social Responsibility (CSR) agenda. CSR that supports Governmental priorities could help companies to benefit significantly from the Governmental industrial policy. We sought to determine whether CSR activities of Brazilian pharmaceutical firms are currently aligned with the Federal Government’s health prioritization. To do so we examined key Brazilian health related policies since 2004, including the specific priorities of Brazil’s 2012–2015 Health Plan, and compared these with CSR initiatives that are reported on the websites of select pharmaceutical firms in Brazil.
Results
Brazil’s national health plans and industrial policies demonstrated that the Federal Government has followed diverse approaches for improving access to medicines, including strengthening health care infrastructure, increasing transparency, and supporting product development partnerships. Case studies of six pharmaceutical firms, representing both public and private companies of varying size, support the perspective that CSR is a priority for firms. However, while many programs target issues such as health infrastructure, health care training, and drug donation, more programs focus on areas other than health and do not seem to be connected to Governmental prioritization.
Conclusion
This research suggests that there are loose connections between Governmental priorities and pharmaceutical firm CSR. However, there remains a significant opportunity for greater alignment, which could improve access to medicines in the country and foster a stronger relationship between the Government and industry.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines) – Volume 13, Issue 2, 2017

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 13, Issue 2, 2017
http://www.tandfonline.com/toc/khvi20/current

Review article
Meningococcal serogroup B vaccines: Estimating breadth of coverage
Pages: 255-265
Published online: 14 Dec 2016
Robert G. K. Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R. Jones, Shannon L. Harris, John L. Perez, Joseph J. Eiden, Kathrin U. Jansen & Annaliesa S. Anderson

Article
Why, when and for what diseases pregnant and new mothers “should” be vaccinated
Pages: 283-290
Published online: 08 Dec 2016
Giovanni Gabutti, Giorgio Conforti, Alberto Tomasi, Parvanè Kuhdari, Paolo Castiglia, Rosa Prato, Silvia Memmini, Chiara Azzari, Giovanni Vitali Rosati & Paolo Bonanni

Article
Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis
Pages: 298-305
Published online: 14 Dec 2016
Masaji Okada, Yoko Kita, Satomi Hashimoto, Hitoshi Nakatani, Shiho Nishimastu, Yumiko Kioka & Yasuko Takami

Review article
Recommended vaccinations for asplenic and hyposplenic adult patients
Pages: 359-368
Published online: 08 Dec 2016
Paolo Bonanni, Maddalena Grazzini, Giuditta Niccolai, Diana Paolini, Ornella Varone, Alessandro Bartoloni, Filippo Bartalesi, Maria Grazia Santini, Simonetta Baretti, Carlo Bonito, Paola Zini, Maria Teresa Mechi, Fabrizio Niccolini, Lea Magistri, Maria Beatrice Pulci, Sara Boccalini & Angela Bechini

Article
Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: The ESCULAPIO project
Pages: 369-375
Published online: 19 Feb 2017
Angela Bechini, Paolo Bonanni, Sara Lauri, Emilia Tiscione, Miriam Levi, Rosa Prato, Francesca Fortunato, Domenico Martinelli, Roberto Gasparini, Donatella Panatto, Daniela Amicizia, Rosa Cristina Coppola, Barbara Pellizzari, Garden Tabacchi, Claudio Costantino, Francesco Vitale, Stefania Iannazzo & Sara Boccalini

Article
Clinical and economic impact of herpes zoster vaccination in elderly in Italy
Pages: 405-411
Published online: 07 Dec 2016
Sara Boccalini, Cristiano Alicino, Domenico Martinelli, Angela Bechini, Emilia Tiscione, Barbara Pellizzari, Rosa Prato, Giancarlo Icardi, Stefania Iannazzo & Paolo Bonanni

Article
How often people google for vaccination: Qualitative and quantitative insights from a systematic search of the web-based activities using Google Trends
Pages: 464-469
Published online: 16 Dec 2016
Nicola Luigi Bragazzi, Ilaria Barberis, Roberto Rosselli, Vincenza Gianfredi, Daniele Nucci, Massimo Moretti, Tania Salvatori, Gianfranco Martucci & Mariano Martini

JAMA – February 21, 2017, Vol 317, No. 7, Pages 663-780

JAMA
February 21, 2017, Vol 317, No. 7, Pages 663-780
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Emerging and Reemerging Infectious Diseases – The Dichotomy Between Acute Outbreaks and Chronic Endemicity
Catharine I. Paules, MD; Anthony S. Fauci, MD
JAMA. 2017;317(7):691-692. doi:10.1001/jama.2016.21079
This Viewpoint discusses the importance of continuing infectious diseases research, even after outbreaks subside and disease progression becomes endemic.

Editorial
Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research
Steven N. Goodman, MD, MHS, PhD; Sebastian Schneeweiss, MD, ScD; Michael Baiocchi, PhD
JAMA. 2017;317(7):705-707. doi:10.1001/jama.2016.19970

Academic-Community Partnership for Medical Missions: Lessons Learned and Practical Guidance for Global Health Service-Learning Experiences

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 28, Number 1, February 2017
https://muse.jhu.edu/issue/35850

Reports from the Field
Academic-Community Partnership for Medical Missions: Lessons Learned and Practical Guidance for Global Health Service-Learning Experiences
pp. 8-13
Yen H. Dang, Frank J. Nice, Hoai-An Truong

Public health aspects of the world’s largest mass gathering: The 2013 Kumbh Mela in Allahabad, India

Journal of Public Health Policy
Volume 37, Issue 4, December 2016
http://link.springer.com/journal/41271/37/4/page/1

Original Article
Public health aspects of the world’s largest mass gathering: The 2013 Kumbh Mela in Allahabad, India
Satchit Balsari, P. Gregg Greenough, Dhruv Kazi, Aaron Heerboth, Shraddha Dwivedi, Jennifer Leaning
Abstract
India’s Kumbh Mela remains the world’s largest and longest mass gathering. The 2013 event, where participants undertook a ritual bath, hosted over 70 million Hindu pilgrims during 55 days on a 1936 hectare flood plain at the confluence of the Yamuna and Ganga Rivers. On the holiest bathing days, the population surged. Unlike other religious, cultural, and sports mass gatherings, the Kumbh Mela’s administration cannot estimate or limit the participant number. The event created serious and uncommon public health challenges: initiating crowd safety measures where population density and mobility directly contact flowing bodies of water; providing water, sanitation, and hygiene to a population that frequently defecates in the open; and establishing disease surveillance and resource use measures within a temporary health delivery system. We review the world’s largest gathering by observing first-hand the public health challenges, plus the preparations for and responses to them. We recommend ways to improve preparedness.

The Lancet – Feb 25, 2017 – Volume 389 Number 10071 p763-880

The Lancet
Feb 25, 2017 Volume 389 Number 10071 p763-880
http://www.thelancet.com/journals/lancet/issue/current

Series
Health, equity, and women’s cancers
The global burden of women’s cancers: a grand challenge in global health
Ophira Ginsburg, Freddie Bray, Michel P Coleman, Verna Vanderpuye, Alexandru Eniu, S Rani Kotha, Malabika Sarker, Tran Thanh Huong, Claudia Allemani, Allison Dvaladze, Julie Gralow, Karen Yeates, Carolyn Taylor, Nandini Oomman, Suneeta Krishnan, Richard Sullivan, Dominista Kombe, Magaly M Blas, Groesbeck Parham, Natasha Kassami, Lesong Conteh

Health, equity, and women’s cancers
Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries
Lynette Denny, Silvia de Sanjose, Miriam Mutebi, Benjamin O Anderson, Jane Kim, Jose Jeronimo, Rolando Herrero, Karen Yeates, Ophira Ginsburg, Rengaswamy Sankaranarayanan

Health, equity, and women’s cancers
Changing global policy to deliver safe, equitable, and affordable care for women’s cancers
Ophira Ginsburg, Rajan Badwe, Peter Boyle, Gemma Derricks, Anna Dare, Tim Evans, Alexandru Eniu, Jorge Jimenez, Tezer Kutluk, Gilberto Lopes, Sulma I Mohammed, You-Lin Qiao, Sabina Faiz Rashid, Diane Summers, Diana Sarfati, Marleen Temmerman, Edward L Trimble, Aasim I Padela, Ajay Aggarwal, Richard Sullivan

No publication without confirmation

Nature
Volume 542 Number 7642 pp392-512 23 February 2017
http://www.nature.com/nature/current_issue.html

Comment
No publication without confirmation
Jeffrey S. Mogil and Malcolm R. Macleod propose a new kind of paper that combines the flexibility of basic research with the rigour of clinical trials.
Concern over the reliability of published biomedical results grows unabated. Frustration with this ‘reproducibility crisis’ is felt by everyone pursuing new disease treatments: from clinicians and would-be drug developers who want solid foundations for the preclinical research they build on, to basic scientists who are forced to devote more time and resources to newly imposed requirements for rigour, reporting and statistics. Tightening rigour across all experiments will decrease the number of false positive findings, but comes with the risk of reducing experimental efficiency and creativity.

Bolder ideas are needed. What we propose here is a compromise between the need to trust conclusions in published papers and the freedom for basic scientists to explore and innovate1. Our proposal is a new type of paper for animal studies of disease therapies or preventions: one that incorporates an independent, statistically rigorous confirmation of a researcher’s central hypothesis. We call this large confirmatory study a preclinical trial. These would be more formal and rigorous than the typical preclinical testing conducted in academic labs, and would adopt many practices of a clinical trial.

We believe that this requirement would push researchers to be more sceptical of their own work. Instead of striving to convince reviewers and editors to publish a paper in prestigious outlets, they would be questioning whether their hypotheses could stand up in a large, confirmatory animal study. Such a trial would allow much more flexibility in earlier hypothesis-generating experiments, which would be published in the same paper as the confirmatory study. If the idea catches on, there will be fewer high-profile papers hailing new therapeutic strategies, but much more confidence in their conclusions…

Does Zika Virus Cause Microcephaly – Applying the Bradford Hill Viewpoints

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
[Accessed 25 February 2017]

Research Article
Does Zika Virus Cause Microcephaly – Applying the Bradford Hill Viewpoints
February 22, 2017 · Research Article
Introduction: Zika virus has been documented since 1952, but been associated with mild, self-limiting disease. Zika virus is classified as an arbovirus from a family of Flaviviridae and primarily spread by Aedes Aegypti mosquitos. However, in a large outbreak in Brazil in 2015, Zika virus has been associated with microcephaly.
Methods: In this review we applied the Bradford-Hill viewpoints  to investigate the association between Zika virus and microcephaly. We examined historical studies, available data and also compared historical rates of microcephaly prior to the Zika virus outbreak. The available evidence was reviewed against the Bradford Hill viewpoints.
Results: All  the nine criteria were met to varying degrees: strength of association, consistency of the association, specificity, temporality, plausibility, coherence, experimental evidence, biological gradient and analogy.
Conclusion: Using the Bradford Hill Viewpoints as an evaluation framework for causation is highly suggestive that the association between Zika virus and microcephaly is causal. Further studies using animal models on the viewpoints which were not as strongly fulfilled would be helpful.

Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 25 February 2017)

Essay
Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints
Evelinn Mikkelsen, Jan A. C. Hontelez, Maarten P. M. Jansen, Till Bärnighausen, Katharina Hauck, Kjell A. Johansson, Gesine Meyer-Rath, Mead Over, Sake J. de Vlas, Gert J. van der Wilt, Noor Tromp, Leon Bijlmakers, Rob M. P. M. Baltussen
| published 21 Feb 2017 P
http://dx.doi.org/10.1371/journal.pmed.1002240

Housing Improvements and Malaria Risk in Sub-Saharan Africa: A Multi-Country Analysis of Survey Data

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 25 February 2017)

Research Article
Housing Improvements and Malaria Risk in Sub-Saharan Africa: A Multi-Country Analysis of Survey Data
Improvements to housing may contribute to malaria control and elimination by reducing house entry by malaria vectors and thus exposure to biting. We tested the hypothesis that the odds of malaria infection are lower in modern, improved housing compared to traditional housing in sub-Saharan Africa (SSA).
Lucy S. Tusting, Christian Bottomley, Harry Gibson, Immo Kleinschmidt, Andrew J. Tatem, Steve W. Lindsay, Peter W. Gething
| published 21 Feb 2017 P
http://dx.doi.org/10.1371/journal.pmed.1002234

Global urbanization and the neglected tropical diseases

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 25 February 2017)

Editorial
Global urbanization and the neglected tropical diseases
Peter J. Hotez
| published 23 Feb 2017 P
http://dx.doi.org/10.1371/journal.pntd.0005308
Increasing urbanization in both developing and developed countries could promote the emergence of a new set of neglected tropical diseases (NTDs)
…Overall, there is a dearth of information about the urban transmission of NTDs and very few disease burden estimates that distinguish urban versus rural modes of transmission. As global urbanization continues to increase, there is going to be an urgent need for such studies. By 2050, with most of the global population living in cities, we will need to better understand how NTDs and other poverty-related neglected diseases flourish in urban environments.
The UN is beginning to shape new public policies for global urbanization, which include programs for balanced urban growth and spatial distribution, sustainability, and timely collection of data required for urban planning [1]. The findings of significant and serious NTDs in urban areas mean that these diseases will also need to be considered as urban areas and megacities strive to meet their SDGs. Arbovirus infections, leptospirosis, cholera, and typhoid fever, vector-borne parasitic infections such as schistosomiasis, Chagas disease, leishmaniasis, and vivax malaria, and NTD–NCD comorbidities each represent the product of urban planning breakdowns and unchecked growth. Without adequate public health measures and research and development for new drugs, diagnostics, and vaccines, we can expect that these diseases will continue to thwart sustainable urban growth in the coming decades.

Product development programs for neglected tropical diseases: A crucial role for expert meetings

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 25 February 2017)

Symposium
Product development programs for neglected tropical diseases: A crucial role for expert meetings
Leonie Hussaarts, Kim van der Weijde, Pierre Dome, Elly Kourany-Lefoll, Jutta Reinhard-Rupp, Remco de Vrueh, on behalf of the Pediatric Praziquantel Consortium
| published 23 Feb 2017 P
http://dx.doi.org/10.1371/journal.pntd.0005183

PLoS One

PLoS One
http://www.plosone.org/
[Accessed 25 February 2017]

Research Article
Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali
Ibrahima Téguété, Amadou Dolo, Kotou Sangare, Abdoulaye Sissoko, Mali Rochas, Sarah Beseme, Karamoko Tounkara, Shahla Yekta, Anne S. De Groot, Ousmane A. Koita
| published 23 Feb 2017 P
http://dx.doi.org/10.1371/journal.pone.0172661

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study
Andrew Schumacher, William M. Sikov, Matthew I. Quesenberry, Howard Safran, Humera Khurshid, Kristen M. Mitchell, Adam J. Olszewski
Research Article | published 24 Feb 2017 P
http://dx.doi.org/10.1371/journal.pone.0172957

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms’ innovation performance
K. D. S. Fernald, H. P. G. Pennings, J. F. van den Bosch, H. R. Commandeur, E. Claassen
Research Article | published 23 Feb 2017 P
http://dx.doi.org/10.1371/journal.pone.0172488

Effect of maternal death on child survival in rural West Africa: 25 years of prospective surveillance data in The Gambia
Susana Scott, Lindsay Kendall, Pierre Gomez, Stephen R. C. Howie, Syed M. A. Zaman, Samba Ceesay, Umberto D’Alessandro, Momodou Jasseh
Research Article | published 22 Feb 2017 P
http://dx.doi.org/10.1371/journal.pone.0172286

Approving new drugs

Science
24 February 2017 Vol 355, Issue 6327
http://www.sciencemag.org/current.dtl

Editorial
Approving new drugs
By John L. LaMattina
Science24 Feb 2017 : 777
As the Trump administration takes shape, there is much speculation as to what major changes will be made. A dominant theme of the Trump campaign was to cut through bureaucracy in Washington, D.C., thereby enhancing innovation and bringing new technology to Americans more quickly. Nowhere could such a philosophical change have more impact than on Food and Drug Administration (FDA) approval of new drugs.

Decades ago, it was not unusual for the FDA to approve a drug simply on the basis of its effect on disease biomarkers. For example, approval of the first statins, including Merck’s Mevacor and Zocor, was based on their ability to lower low-density lipoprotein (LDL) cholesterol, known to be associated with the buildup of deadly atherosclerotic plaque. It wasn’t until many years later that long-term clinical trials involving thousands of patients actually proved that these drugs reduced heart attacks and strokes.

However, there are far more examples of drugs that failed to provide the desired health outcome despite having favorable effects on disease biomarkers. One example comes from another class of lipid modulators, the cholesteryl ester transfer protein inhibitors (CETPis). When discovered, these drugs looked promising in that they raised high-density lipoprotein (HDL) cholesterol, long associated with cardioprotection, as well as lowered LDL cholesterol, thereby completely remodeling the lipoprotein profile of patients with heart disease. Despite their promise, the FDA would not approve a CETPi without evidence that it did in fact reduce adverse cardiovascular outcomes. To date, clinical trials for these drugs have shown that they do not reduce heart attacks and, in one case, actually increased deaths.

Such occurrences are not exclusive to the cardiovascular field. For Alzheimer’s disease (AD), several companies have discovered experimental drugs that reduce the level of amyloid proteins, which are believed to be an initiating factor in AD. However, despite successfully lowering amyloid levels in AD patients, long-term studies showed that these drugs do not improve cognition in this population. These examples are not unique. There are cases where drugs that lower plasma glucose do not prevent the adverse health consequences of diabetes, and where drugs that shrink tumors do not reduce cancer deaths. Favorably affecting disease biomarkers is an important step in drug research and development (R&D) because it indicates that the experimental drug could potentially prevent the long-term consequences of disease. However, only long-term clinical trials, although time-consuming and expensive, can prove the value of a new medicine.

President Trump and Tom Price, the newly sworn-in Secretary of Health and Human Services (which oversees the FDA) want to streamline the FDA’s approval process for drugs. But changing the current drug approval paradigm would hurt everyone. What if the FDA simply rules that early-stage drugs are safe solely on the basis of biomarker effects? Suppose doctors and patients decide on whether to take such a drug with unproven long-term effects? This would certainly get experimental drugs to patients faster and enable companies to recoup their R&D investment more quickly. However, based on historical precedent, many of the drugs approved in this way would be ineffective. At best, they would be glorified placebos. At worst, they could prove harmful. As a result, patients would not have benefited by taking such a drug, physicians would be called into question for prescribing such a drug, payers would have wasted millions (even billions) of dollars reimbursing the costs of such a drug, and companies would face the inevitable lawsuits that arise in these situations. Everyone loses.

Over the years, the FDA has learned that, for many diseases, it is important that the drug maker prove the benefits of the drug before unleashing it on the public. Does this slow the process and greatly add to the R&D costs? Absolutely. But it is good medical practice.

Vaccine – Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)

Vaccine
Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/9

.

Commentary
Early sexual debut warrants HPV vaccination at an earlier age
Pages 1195-1196
Abbey B. Berenson, Sharon Croisant

.

WHO Reports
Polio vaccines: WHO position paper, March 2016–recommendations
Pages 1197-1199
World Health Organization

Dengue vaccine: WHO position paper, July 2016 – recommendations
Pages 1200-1201
World Health Organization

Polio eradication in the African Region on course despite public health emergencies
Pages 1202-1206
Joseph C. Okeibunor, Martin C. Ota, Bartholomew D. Akanmori, Nicksy Gumede, Keith Shaba, Koffi I. Kouadio, Alain Poy, Richard Mihigo, Mbaye Salla, Matshidiso R. Moeti

US medical students’ willingness to offer the HPV vaccine by vaccination status

Vaccine
Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/9

Short communication
US medical students’ willingness to offer the HPV vaccine by vaccination status
Pages 1212-1215
Abbey B. Berenson, Jacqueline M. Hirth, Erika L. Fuchs, the Multidisciplinary Translation Team on Reproductive Women’s Health
Abstract
We surveyed third-year medical students to assess whether personal vaccination status was associated with willingness to recommend the human papillomavirus vaccine to patients. A total of 231 students completed an anonymous survey evaluating their knowledge, attitudes, and personal vaccine history. Of 122 female students, 81 (66.4%) reported initiating the vaccine, as did 16 of 109 males (14.7%). Females and students ⩽25 years old were more likely to be vaccinated. Knowledge did not vary by vaccination status, but anticipated behaviors did. Vaccinated students reported greater willingness to vaccinate adolescents before 15–16 years of age (92.1% vs. 78.6%, p = 0.008) and discuss vaccination at any type of medical visit (100% vs. 89.7%, p < 0.001). Our findings suggest that prior experiences with the HPV vaccine may influence a provider’s future actions. Thus, interventions that increase awareness of this relationship as well as vaccination rates among health care students may be beneficial.

Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010–2014

Vaccine
Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/9

Original Research Article
Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010–2014
Pages 1281-1286
Yan Liu, Jun Wang, Shijun Liu, Jian Du, Liang Wang, Wenwen Gu, Yuyang Xu, Shuyan Zuo, Erping Xu, Zhijie An
Abstract
Background
China’s Expanded Program on Immunization (EPI) has provided 4 doses of oral poliovirus vaccine (OPV) since the 1970s. Inactivated poliovirus vaccine (IPV) became available in 2010 in Hangzhou as a private-sector, parent-chosen alternative to OPV. In 2015, WHO recommended that countries with all-OPV vaccination schedules introduce at least one dose of IPV, to mitigate risk associated with the withdrawal of type 2 OPV. We analyzed polio vaccine coverage and utilization in Hangzhou to determine patterns of IPV use and the occurrence of vaccine-associated paralytic polio (VAPP) in the various patterns identified.
Methods
Children born between 2010 and 2014 and registered in Hangzhou’s Immunization Information System (HZIIS) were included. VAPP cases were detected through the acute flaccid paralysis surveillance system. We used descriptive epidemiological methods to determine IPV and OPV usage patterns and VAPP occurrence.
Results
HZIIS data from 566,894 children were analyzed. Coverage levels of polio vaccine were greater than 92% for each birth cohort. Percentages of children using OPV-only, IPV-only, and IPV/OPV sequential schedules were 70.57%, 27.01% and 2.41%, respectively. IPV-only schedule utilization increased by birth cohort regardless of geographical area or whether the child was locally-born. The highest use of an all-IPV schedule (79.85%) was among urban, locally-born children in the 2014 birth cohort. Five VAPP cases were identified during the study years; all cases occurred following the first polio vaccine dose, which was always OPV for the cases. Type 2 vaccine virus was isolated from 2 VAPP cases, and type 2 and type 3 vaccine virus was isolated from one VAPP case. The incidence of VAPP in the 2010–2014 birth cohorts was 3.76 per 1 million doses of OPV.
Conclusion
Children in Hangzhou had high polio vaccination coverage. IPV-only schedule use increased by year, and was highest in urban areas among locally-born children. All cases of VAPP were associated with the first dose of OPV.

Impact of vaccination on influenza mortality in children <5 years old in Mexico

Vaccine
Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/9

Impact of vaccination on influenza mortality in children
Original Research Article
Pages 1287-1292
Evelyn L. Sánchez-Ramos, Joel Monárrez-Espino, Daniel E. Noyola
Abstract
Background
Influenza is a leading cause of respiratory tract infections among children. In Mexico, influenza vaccination was included in the National Immunization Program since 2004. However, the population health effects of the vaccine on children have not been fully described. Thus, we estimated the impact of influenza immunization in terms of mortality associated with this virus among children younger than 5 years of age in Mexico.
Methods
Mortality rates and years of life lost associated with influenza were estimated using national mortality register data for the period 1998–2012. Age-stratified and cause-specific mortality rates were estimated for all-cause, respiratory and cardiovascular events. Influenza-associated mortality was compared between the period prior to introduction of the influenza vaccine as part of the National Immunization Program (1998–2004) and the period thereafter (2004–2012).
Results
During the 1998–2012 winter seasons, the average number of all-cause, respiratory and cardiovascular deaths attributable to influenza were 1186, 794 and 21, respectively. Influenza-associated mortality was higher prior to the vaccination period than after influenza was included in the immunization program for all-cause (mean 1660 vs. 780) and respiratory (mean 1063 vs. 563) mortality, but no reduction was seen for cardiovascular mortality. The proportion of all-cause and respiratory deaths attributable to influenza was significantly lower in the post-vaccine period compared with the pre-vaccine period (P < 0.001), but no reduction was seen in the proportion of cardiovascular deaths. There was an average annual reduction of 66,558 years of life lost in the post-vaccine compared with the pre-vaccine period.
Conclusion
The introduction of influenza vaccination within the Mexican Immunization Program was associated with a reduction in mortality rates attributable to this virus among children younger than 5 years of age.

Integration of data from a safety net health care system into the Vaccine Safety Datalink

Vaccine
Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/9

Integration of data from a safety net health care system into the Vaccine Safety Datalink
Original Research Article
Pages 1329-1334
Simon J. Hambidge, Colleen Ross, Jo Ann Shoup, Kris Wain, Komal Narwaney, Kristin Breslin, Eric S. Weintraub, Michael M. McNeil
Abstract
Background
In 2013 the Institute of Medicine suggested that the Vaccine Safety DataLink (VSD) should broaden its population by including data of more patients from low income and racially and ethnically diverse backgrounds. In response, Kaiser Permanente Colorado (KPCO) partnered with Denver Health (DH), an integrated safety net health care system, to explore the integration of DH data.
Methods
We compared three different methods (reference date of September 1, 2013): “Empanelment” (any patient who has had a primary care visit in the past 18 months), “Proxy-enrollment” (two health care visits in 3 years separated by 90 days), and “Enrollment” in a managed care plan. For each of these methods, we compared cohort size, vaccination rates, socio-demographic characteristics, and health care utilization.
Results
The empaneled population at DH provided the best comparison to KPCO. DH’s empaneled population was 111,330 (57,173 adults; 54,157 children), while KPCO had 436,290 empaneled patients (336,462 adults; 99,828 children). Vaccination rates in both health care systems for empaneled patients were comparable. Two year-old up-to-date coverage rates were 83.2% (KPCO) and 86.9% (DH); rates for adolescent Tdap and MCV4 were 85.5% (KPCO) and 90.6% (DH). There were significant differences in the two populations in age, gender, race, preferred language, and % Federal Poverty Level (FPL) (DH 70.7% < 100% FPL; KPCO 17.4%), as well as in healthcare utilization – for example pediatric emergency department utilization was twice as high at DH.
Conclusions
Using a cohort of “empaneled” patients, it is possible to integrate data from a safety net health care system that does not have a uniform managed care population into the VSD, and to compare vaccination rates, socio-demographic characteristics, and health care utilization across the two systems. The KPCO-DH collaboration may serve as a model for incorporating data from a safety net healthcare system into the VSD.

Recommendations and offers for adult influenza vaccination, 2011–2012 season, United States

Vaccine
Volume 35, Issue 9, Pages 1195-1368 (1 March 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/9

Recommendations and offers for adult influenza vaccination, 2011–2012 season, United States
Original Research Article
Pages 1353-1361
Katharine M. Benedict, Tammy A. Santibanez, Carla L. Black, Helen Ding, Samuel B. Graitcer, Carolyn B. Bridges, Erin D. Kennedy
Abstract
Background
Provider recommendations and offers for influenza vaccination improve adult influenza vaccination coverage. Analysis was performed to describe receipt of influenza vaccination recommendations and offers among adults who visited a healthcare provider (HCP) during the 2011–2012 influenza season and describe differences between those receiving and not receiving recommendations and offers for influenza vaccination. Associations between influenza vaccination and receipt of recommendations and offers were examined.
Methods
Respondents to a random digit dial telephone survey who had visited a HCP since July 1, 2011 were asked if they had received a recommendation for influenza vaccination. Those receiving a recommendation were asked if they received an offer for vaccination. Participants were characterized by demographic and access to health care variables. Logistic regression was used to examine the relationships between participant characteristics and recommendation alone, between participant characteristics and recommendation and offer, and between influenza vaccination and recommendation and offer.
Results
Of those who reported visiting a HCP, 43.8% reported receiving a recommendation for influenza vaccination. Of those who reported receiving a recommendation, 76.6% reported receiving an offer for influenza vaccination. Persons with high-risk conditions and persons over 65 years were more likely to receive recommendations for influenza vaccination when compared to those without high-risk conditions and 18–49 year olds, respectively. Those reporting receipt of a recommendation and offer for influenza vaccination were 1.76 times more likely and those reporting receipt of a recommendation but no offer were 1.72 times more likely to report being vaccinated for influenza controlling for all patient characteristics.
Conclusions
Less than half of respondents reported receipt of recommendations and offers of influenza vaccination during the 2011–2012 influenza season and disparities exist between groups. All healthcare providers seeing adults should recommend or offer influenza vaccination for all patients at every visit during the influenza season.

Addressing Gaps in Cost-Effectiveness Analysis Using Cost-Effectiveness Analysis to Address Health Equity Concerns

Value in Health
February 2017 Volume 20, Issue 2, p181-308
http://www.valueinhealthjournal.com/current

Addressing Gaps in Cost-Effectiveness Analysis Using Cost-Effectiveness Analysis to Address Health Equity Concerns
Richard Cookson, Andrew J. Mirelman, Susan Griffin, Miqdad Asaria, Bryony Dawkins, Ole Frithjof Norheim, Stéphane Verguet, Anthony J. Culyer
p206–212
Published in issue: February 2017
Abstract
This articles serves as a guide to using cost-effectiveness analysis (CEA) to address health equity concerns. We first introduce the “equity impact plane,” a tool for considering trade-offs between improving total health—the objective underpinning conventional CEA—and equity objectives, such as reducing social inequality in health or prioritizing the severely ill. Improving total health may clash with reducing social inequality in health, for example, when effective delivery of services to disadvantaged communities requires additional costs. Who gains and who loses from a cost-increasing health program depends on differences among people in terms of health risks, uptake, quality, adherence, capacity to benefit, and—crucially—who bears the opportunity costs of diverting scarce resources from other uses. We describe two main ways of using CEA to address health equity concerns: 1) equity impact analysis, which quantifies the distribution of costs and effects by equity-relevant variables, such as socioeconomic status, location, ethnicity, sex, and severity of illness; and 2) equity trade-off analysis, which quantifies trade-offs between improving total health and other equity objectives. One way to analyze equity trade-offs is to count the cost of fairer but less cost-effective options in terms of health forgone. Another method is to explore how much concern for equity is required to choose fairer but less cost-effective options using equity weights or parameters. We hope this article will help the health technology assessment community navigate the practical options now available for conducting equity-informative CEA that gives policymakers a better understanding of equity impacts and trade-offs.

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Annals of the NY Academy of Sciences
23 February 2017
CONCISE ORIGINAL REPORT
Human capital gaps in vaccine development: an issue for global vaccine development and global health
Cawein, A., Emini, E., Watson, M., Dailey, J., Donnelly, J., Tresnan, D., Evans, T., Plotkin, S. and Gruber, W.
doi:10.1111/nyas.13316
Abstract
Despite the success of vaccines in reducing the morbidity and mortality associated with infectious diseases, many infectious diseases, both newly emerging and well known, lack vaccines. The global capability for beginning-to-end vaccine development has become limited, primarily owing to a scarcity of human capital necessary to guide the development of novel vaccines from the laboratory to the marketplace. Here, we identify and discuss the gaps in human capital necessary for robust vaccine development and make recommendations to begin to address these deficiencies.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

Der Spiegel
http://www.spiegel.de/
Accessed 25 February 2017
Bill Gates Interview
I Told Trump ‘How Wonderful’ Vaccines Are
22 February 2017
Amid wars, fake news and Donald Trump, the risk of a global pandemic is getting little attention these days. In an interview, Microsoft founder and philanthropist Bill Gates warns of the dramatic consequences.

.

Forbes
http://www.forbes.com/
Accessed 25 February 2017
A West Virginian Is Trying To Stop A Senate Bill From Destroying State Vaccination Rates
Kavin Senapathy, Contributor
Feb 23, 2017
Similar anti-vaccine bills have fizzled out but Meredith Snead is taking no chances. The health of West Virginians and the nation are at stake.

Dear Robert Kennedy Jr.: Here Are Two People You Can Give $100,000
18 February 2017
Bruce Y. Lee,  Contributor
Dear Robert Kennedy, Jr., I heard that you have offered $100,000 to anyone who could find a study showing that it’s safe to administer vaccines to children and pregnant women (as indicated in the Washington Post). Actor and Director Robert De Niro was present during the announcement to offer his endorsement. It’s great that you are committing publicly to support medical research. Hope you have a lot of money (this site says $50 million but I don’t know if this has been verified) because there have been a lot of vaccine safety studies out there. Well, to start, if you have a pen handy, here are two people whom you can make the check out to: Dr. Neal Halsey and Dr. Dan Salmon. That’s Neal with an “ea” and Salmon, spelled like the fish…

.

Fortune
http://fortune.com/
Accessed 25 February 2017
What Bill and Melinda Gates See That Donald Trump Doesn’t
| 17 February 2017
… It’s no surprise that the cofounder of Microsoft is a techno-enthusiast, but the most high-impact technology for improving global health, Bill and Melinda Gates argue, are simple vaccines. It’s hard to overstate their enthusiasm for the potential of a “basic package” of childhood vaccines to save lives, reduce the cost of healthcare, and unleash economic productivity. The worldwide vaccination rate is the highest it’s ever been (86%,), they explain, thanks in large part to a global Vaccine Alliance that has immunized 580 million children. Vaccines “are one of the great things the rich world does for the rest of the world,” Bill Gates notes, and “for every dollar spent on childhood immunizations, you get $44 of economic benefit.”…

.

New York Times
http://www.nytimes.com/
Accessed 25 February 2017
The Anti-Vaccine Movement Gains a Friend in the White House
23 February 2017
By THE EDITORIAL BOARD
Vaccine opponents, often the subject of ridicule, have found fresh energy in the election of a president who has repeated discredited claims linking childhood immunizations to autism and who has apparently decided to pursue them. With President Trump’s support, this fringe movement could win official recognition, threatening lives and making it urgent that health officials, educators and others respond with a science-based defense of vaccines.

Vaccines have saved lives by protecting children and adults from diseases like measles, polio, smallpox, cervical cancer and whooping cough. And there is no evidence whatsoever that vaccines or a preservative used in flu shots cause autism. Scientists have also shown that parents who refuse to immunize their children are threatening to undo decades of public health gains.

Yet, activists like Robert Kennedy Jr. continue to push pseudoscience about immunizations. The terrifying thing is that they appear to have Mr. Trump’s ear. After a meeting with the president last month, Mr. Kennedy said that the president would name him to head a new committee on vaccine safety; the government already has an advisory group that is meeting this week. And last week, during a news conference with Robert De Niro, Mr. Kennedy offered a $100,000 reward to anyone who could prove that vaccines are safe for children and pregnant women.
Of course, countless studies show that vaccines are safe and effective — more than 350 health groups compiled a list for Mr. Trump — but they haven’t penetrated the reality distortion field created by Mr. Kennedy and his fellow travelers. The biggest danger is that their movement will sow enough doubt that more parents will refuse to let their children be immunized. In some states like Texas the number of children who do not receive vaccines has risen sharply over the last decade and is now in the tens of thousands. Not only does this increase the risk of infections to the youths who don’t get shots, but it also threatens infants who are too young and children who cannot be vaccinated for medical reasons. This phenomenon has already led to outbreaks of measles and mumps.

Some parents are understandably anxious about autism. But scientists say there are several possible explanations for why more children have been found to have autism spectrum disorders in recent years, and none of them are linked to vaccines. Doctors have gotten better at identifying those conditions. Genetic factors could be at play, as well as fetal brain defects that develop during pregnancy because of exposure to chemicals and infections.

Mr. Trump does not have the authority to change vaccination requirements for schools and day care centers. States set those rules and determine whether families can opt out based on religious or personal beliefs. But he has a bully pulpit and appoints the heads of health agencies. People who care about public health ought to pressure Mr. Trump not to empower this antiscience movement.

The good news is that members of Congress are pushing back. Six influential lawmakers from both parties, including Senators Lamar Alexander, Republican of Tennessee, and Patty Murray, Democrat of Washington, sent a letter to their colleagues on Tuesday declaring, “Simply put, vaccines save lives.”

Vaccines and Global Health : The Week in Review :: 18 February 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: vaccines-and-global-health_the-week-in-review_18-february-2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives

Twelfth meeting of the Emergency Committee under the International Health Regulations (2015) regarding the international spread of poliovirus
[Excerpts; text bolding by Editor]
13 February 2017 – The twelfth meeting of the Emergency Committee (EC) under the International Health Regulations (2005) (IHR) regarding the international spread of poliovirus was convened via teleconference by the Director General on 7 February 2017…

Conclusion
The Committee unanimously agreed that the international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC), and recommended the extension of the Temporary Recommendations for a further three months. The Committee considered the following factors in reaching this conclusion:
:: The outbreak of WPV1 and cVDPV in Nigeria highlighting that there are high-risk areas where surveillance is compromised by inaccessibility, resulting in ongoing circulation of WPV for several years without detection. The risk of transmission in the Lake Chad sub-region appears high.
:: The continued international spread of WPV1 between Pakistan and Afghanistan.
:: The persistent, wide geographical distribution of positive WPV1 in environmental samples and AFP cases in Pakistan, while acknowledging the intensification of environmental surveillance inevitably increasing detection rates.
:: The current special and extraordinary context of being closer to polio eradication than ever before in history, with the lowest number of WPV1 cases ever recorded occurring in 2016.
:: The risk and consequent costs of failure to eradicate globally one of the world’s most serious vaccine preventable diseases. Even though global transmission has fallen dramatically and with it the likelihood of international spread, the consequences and impact of international spread should it occur would be grave.
:: The possibility of global complacency developing as the numbers of polio cases continues to fall and eradication becomes a possibility.
:: The serious consequences of further international spread for the increasing number of countries in which immunization systems have been weakened or disrupted by conflict and complex emergencies. Populations in these fragile states are vulnerable to outbreaks of polio. Outbreaks in fragile states are exceedingly difficult to control and threaten the completion of global polio eradication during its end stage.
:: The continued necessity for a coordinated international response to improve immunization and surveillance for WPV1, to stop international spread and reduce the risk of new spread.
:: The importance of a regional approach and strong crossborder cooperation, as much international spread of polio occurs over land borders, while also recognizing that the risk of distant international spread remains from zones with active poliovirus transmission.

:: Additionally with respect to cVDPV:
:: cVDPVs also pose a risk for international spread, which without an urgent response with appropriate measures threatens vulnerable populations as noted above;
:: The ongoing circulation of cVDPV2 in Nigeria and Pakistan, demonstrates significant gaps in population immunity at a critical time in the polio endgame;
:: The ongoing urgency to prevent type 2 cVDPVs following the globally synchronized withdrawal of the type 2 component of the oral poliovirus vaccine in April 2016;
:: The ongoing challenges of improving routine immunization in areas affected by insecurity and other emergencies, including the post Ebola context;
:: The global shortage of IPV which poses an additional threat from cVDPVs

…The Committee strongly urged global partners in polio eradication to provide optimal support to all infected and vulnerable countries at this critical time in the polio eradication programme for implementation of the Temporary Recommendations under the IHR, as well as providing ongoing support to all countries that were previously subject to Temporary Recommendations (Somalia, Ethiopia, Syria, Iraq and Israel).

The committee requested the secretariat to provide data on routine immunization in countries subject to Temporary Recommendations. Recognizing that cVDPV illustrates serious gaps in routine immunization programmes in otherwise polio free countries, the Committee recommended that the international partners in routine immunization, for example Gavi, should assist affected countries to improve the national immunization programme.

The Committee noted the Secretariat’s report on the identification of Sabin 2 virus detected in environmental samples in several countries, and in some of these cases probably due to the ongoing use of tOPV in the private sector. The Committee requested a full report on this at the next meeting.

The Committee noted a more detailed analysis of the public health benefits and costs of implementing temporary recommendations was completed and warranted further discussion and review.

The Committee urged all countries to avoid complacency which could easily lead to a polio resurgence. Surveillance particularly needs careful attention to quickly detect any resurgent transmission.

Based on the advice concerning WPV1 and cVDPV, and the reports made by Afghanistan, Pakistan, Nigeria, and the Central African Republic, the Director General accepted the Committee’s assessment and on 13 February 2017 determined that the events relating to poliovirus continue to constitute a PHEIC, with respect to WPV1 and cVDPV. The Director General endorsed the Committee’s recommendations for countries falling into the definition of ‘States currently exporting WPV1 or cVDPV’, for ‘States infected with WPV1 or cVDPV but not currently exporting’ and for ‘States no longer infected by WPV1, but which remain vulnerable to international spread, and states that are vulnerable to the emergence and circulation of VDPV’ and extended the Temporary Recommendations as revised by the Committee under the IHR to reduce the international spread of poliovirus, effective 13 February 2017.

:::::::
:::::::

Grand challenges for the next decade in global health policy and programmes
Dr Margaret Chan
Director-General of the World Health Organization
Keynote address at a celebration of the 10th anniversary of the University of Washington’s Department of Global Health
Seattle, Washington, USA
8 February 2017
[Editor’s text bolding]
Honourable ministers, distinguished fellow speakers, faculty and staff at the University of Washington, colleagues in public health, ladies and gentlemen,

For global health, this is a jubilee year for the University of Washington’s Department of Global Health and at least seven other Washington-based health organizations.

I congratulate the Department of Global Health on its tenth anniversary celebration. With well over 600 current research projects in nearly 130 countries, your contribution to global health is broad and your productivity is astonishing.

Many of these projects are operating at the cutting edge of innovation and several are being conducted in close collaboration with WHO. Several are dear to my heart, especially in the era of sustainable development…

I have been asked to speak about grand challenges for health policy and programmes in the coming decade.

Your interdisciplinary panels will be exploring four of these challenges: preparedness for outbreaks of emerging and re-emerging diseases, the control of noncommunicable diseases, the health impact of environmental degradation and climate change, and the need for innovative approaches to education and training. I would add antimicrobial resistance, and its nightmare bacteria, to that list.

In our world of radically increased interdependence, the forces that have shaped these challenges are universal, and they are not easily reversed. The world has changed dramatically since the start of this century, when the Millennium Development Goals were put forward as the overarching framework for development cooperation.

World leaders at the Millennium Summit sought to create what they called “a more peaceful, prosperous, and just world”. That did not happen as planned.

To understand the newer challenges now embodied in the 2030 Agenda for Sustainable Development, we need to look at the larger sea in which these trends were set afloat.

Since 2001, terrorist attacks that deliberately target civilians have become more deadly, daring, and common. Armed conflicts are now the largest and longest experienced since the end of World War II. The refugee crisis in Europe taught the world that wars in faraway places will not stay remote.

International humanitarian law is now largely ignored, with the deliberate bombing of health care facilities and the use of siege and starvation as weapons of war.

Warnings about the consequences of climate change are increasingly shrill. Records for extreme weather events are being broken a record number of times. The past three years have been the hottest ever.

The phrase “mega-disaster” entered the humanitarian vocabulary following devastating earthquakes, tsunamis, tropical cyclones, droughts, and floods.

The world population is now bigger, more urban, and a lot older, adding dementia to the list of top health priorities. Everywhere in the world, people are living longer sicker lives, increasing the burden on health services, budgets, and the workforce.

Hunger has persisted, but most of the world got fat. The world has 800 million chronically hungry people, but it also has countries where more than 70% of the adult population is obese or overweight.

The globalized marketing of unhealthy products opened wide the entry point for the rise of lifestyle-related chronic conditions. Noncommunicable diseases have overtaken infectious diseases as the biggest killers worldwide.

This is a unique time in history, where economic progress, improved living conditions, and greater purchasing power are actually increasing diseases instead of reducing them.

Social media have become a new voice with considerable force, yet few safeguards governing the accuracy of its content. The proliferation of front groups and lobbies, protecting commodities that harm health, has created arguments that further muddle public thinking and challenge the authority of evidence.

The Oxford Dictionary of the English Language chose “post-truth” as its word of the year for 2016. In a post-truth, post-fact world, views that appeal to emotions and personal beliefs are more influential than objective evidence-based facts.

What does this mean for public trust in the evidence produced by science, medicine, and public health?

The 21st century has been rocked by the emergence of four new human pathogens: SARS, the H5N1 and H7N9 influenza viruses, and the MERS coronavirus. Other older diseases have remerged in ominous ways, including Ebola, yellow fever, and Zika virus disease.

As the century progressed, more and more first- and second-line antimicrobials failed. The pipeline of replacement products has nearly run dry, raising the spectre of a post-antibiotic era in which common infections will once again kill.

The world is also much richer than at the start of this century. Countries like China and India lifted millions of their citizens out of poverty, but in many countries, the benefits of growing wealth have gone to the privileged few.

The number of rich countries full of poor people has grown, changing the poverty map. Today, 70% of the world’s poor live in middle-income countries.

The consequences of the world’s extreme social inequalities are profound. Last month’s World Economic Forum identified growing inequalities in income and wealth as the single most significant trend that will shape global development over the next ten years.

In essence, the SDGs are a corrective strategy that looks at the root causes of inequality and aims to transform them. The international systems that govern finance, business relations, trade, and foreign affairs need a corrective strategy.

As some critics argue, the long-standing social contract that obliges the privileged few to care for those less fortunate has been broken in a world that has lost its moral compass.

Ladies and gentlemen,
As we collectively address these challenges, I ask you to keep in mind four overarching priorities that should guide health policies and programmes.

First, tackle inequality. Second, improve information. Third, stimulate innovation. Fourth, and above all, show impeccable integrity.

For inequality, the 2030 Agenda for Sustainable Development has the focus right. Leave no one behind. This is not easy, especially in these uncertain times.

Decades of experience tell us that this world will not become a fair place for health all by itself. Health systems will not automatically gravitate towards greater equality or naturally evolve towards universal coverage.

Economic decisions within a country will not automatically protect the poor or promote their health. Globalization will not self-regulate in ways that ensure the fair distribution of benefits. International trade agreements will not, by themselves, guarantee food security, or job security, or health security, or access to affordable medicines.

All of these outcomes require deliberate policy decisions.

I call on you to promote the SDG target for universal health coverage as the ultimate expression of fairness. It is one of the most powerful social equalizers among all policy options.

For information, some 85 countries, representing 65% of the world’s population, do not have reliable cause-of-death statistics. This means that causes of death are neither known nor recorded, and health programmes are left to base their strategies on crude and imprecise estimates. Until more countries have good systems for civil registration and vital statistics, health programmes will be working in the dark, throwing money into a black hole.

This is totally unacceptable in the current climate that places a premium on transparency, accountability, and independent monitoring of results. I am aware of the many current projects, undertaken by the Global Health Department and its partners, which are using the latest information technologies to address precisely this problem.

For innovation, we know that the supremely ambitious health targets set out in the SDGs cannot be met without powerful new medical tools. We know that new vaccines can prevent infections that currently contribute to the overuse of antibiotics.

We know that at least 11 epidemic-prone human pathogens, including the Zika, Lassa fever, and Nipah viruses, have no vaccine to protect populations during outbreaks.

We know that R&D incentives preferentially encourage the development of new products for markets that can pay.

One strategy that has worked well at WHO is to let the people, working in the field and seeing practical constraints on a daily basis, design the profile of an ideal new product, right down to its price. This was the strategy used so successfully in the Meningitis Vaccine Project, funded by the Bill and Melinda Gates Foundation, and coordinated by WHO and PATH. I encourage others to use a similar approach.

Finally, we must all work according to the highest standards of scientific integrity. Like others, I see a number of disturbing trends. Let me respond to just one.

Regulatory agencies everywhere must resist the push to replace randomized clinical trials, long the gold standard for approving new drugs, with research summaries provided by pharmaceutical companies.

As some argue, making this change would speed up regulatory approval, lower the costs to industry, and get more products on the market sooner. This kind of thinking is extremely dangerous.

We must not let anything, including economic arguments or industry pressure, lower our scientific standards or compromise our integrity. This is an absolute duty.

Don’t let politicians, the public, or industry forget the lessons from the thalidomide disaster.
Thank you.

:::::::
:::::::

Editor’s Note:
While we have been monitoring the growing anti-vaccine/vaccine hesitancy “movement” globally, we have not formally designated space in this digest for such content. However, early signals from the new U.S. administration around vaccines and vaccine safety suggest we begin. Below is an announcement we felt warranted inclusion, however incredulous we are about its grounding.

Feb 15, 2017, 11:00 ET
Robert F. Kennedy, Jr. announces the World Mercury Project’s $100,000 challenge with goal of stopping use of highly toxic mercury in vaccines.
…Kennedy announced the “World Mercury Project Challenge” to American journalists and others “who have been assuring the public about the safety of mercury in vaccines.”
Kennedy explained that the WMP will pay $100,000 to the first journalist, or other individual, who can find a peer-reviewed scientific study demonstrating that thimerosal is safe in the amounts contained in vaccines currently being administered to American children and pregnant women….
…Actor Robert De Niro…who also spoke at the press conference, is a supporter of the WMP, whose vision is a world where mercury is no longer a threat to the health of our planet and people. The group focuses on making sound science the driver of public policy…

Emergencies

Emergencies

WHO Grade 3 Emergencies [to 18 February 2017]
Iraq
Iraq: Urgently needed medicines and medical supplies delivered to east Mosul
Erbil 15 February 2017 – The World Health Organization (WHO) has responded to an acute shortage of medical supplies in the newly retaken areas of Mosul by delivering medicines and other medical supplies to 16 primary health centers, one hospital and the Directorate of Health (DOH) in Ninewa. The donation will support treatment of patients with infectious diseases, chronic conditions, diarrheal diseases and trauma cases who have been deprived of medical care.

Nigeria
WHO teams assist people in hard-to-reach areas of Nigeria
17 February 2017 – Medical teams supported by WHO set up mobile clinics in hard to access areas of north-eastern Nigeria. The teams are called “hard-to-reach” teams (HTR) because their mission is to reach remote and insecure areas to provide urgently needed care to populations deprived of essential health services. The 8-year conflict has caused widespread forced displacement and acute food and nutrition insecurity. Large areas of Borno state, the most-affected state, remain inaccessible to humanitarian assistance.

Yemen
:: WHO responds to health needs of populations fleeing conflict in Yemen
February 2017 – As violent conflict continues in Al-Mokha City in Taizz governorate, Yemen, more than more than 8000 internally displaced persons have fled to several other districts. WHO teams in are providing trauma care and primary health care services to newly displaced persons, and delivering medicines and supplies to health facilities.

The Syrian Arab RepublicNo new announcements identified
South Sudan No new announcements identified

::::::
::::::

WHO Grade 2 Emergencies [to 18 February 2017]
Cameroon – No new announcements identified.
Central African Republic – No new announcements identified.
Democratic Republic of the Congo – No new announcements identified.
Ethiopia – No new announcements identified.
Libya – No new announcements identified.
Myanmar – No new announcements identified.
Niger – No new announcements identified.
Ukraine – No new announcements identified.

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises.
Iraq
:: Iraq: Mosul Humanitarian Response Situation Report No. 20 (6 February – 12 February 2017)

Syria
:: Turkey | Syria: Developments in Idleb Governorate and Western Countryside of Aleppo (as of 15 February 2017)
:: 17 Feb 2017 – Syria Operation Overview (January 2017)

Yemen
:: Statement by the Humanitarian Coordinator in Yemen, Jamie McGoldrick, women and children killed by airstrikes in Sana’a [EN/AR] 16 February 2017

::::::
::::::

POLIO [to 18 February 2017]
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 15 February 2017
:: The 12th meeting of the Emergency Committee under the International Health Regulations (IHR) met on 7 February and concluded that current global polio epidemiology continues to constitute a Public Health Emergency of International Concern (PHEIC).  The Temporary Recommendations promulgated under the IHR remain in effect.  National polio emergency action plans continue to be implemented in all countries affected by circulation of either wild poliovirus or vaccine-derived poliovirus, and all countries currently thus affected have declared these events to be a national public health emergency…

Country Updates [Selected Excerpts]
Pakistan
:: One new environmental WPV1 positive sample was reported in the past week, from Killa Abdullah, Balochistan, collected on 19 January.

Twelfth meeting of the Emergency Committee under the International Health Regulations (2015) regarding the international spread of poliovirus
13 February 2017 – The twelfth meeting of the Emergency Committee (EC) under the International Health Regulations (2005) (IHR) regarding the international spread of poliovirus was convened via teleconference by the Director General on 7 February 2017.
[See more detail in Milestones/Perspectives above]

::::::
::::::

Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

Zika virus [to 18 February 2017]
http://www.who.int/emergencies/zika-virus/en/
Latest Report [now bi-weekly]:
Zika situation report – 2 February 2017
Full report: http://apps.who.int/iris/bitstream/10665/254507/1/zikasitrep2Feb17-eng.pdf?ua=1
Analysis
Overall, the global risk assessment has not changed. Zika virus continues to spread geographically to areas where competent vectors are present. Although a decline in cases of Zika infection has been reported in some countries, or in some parts of countries, vigilance needs to remain high.

:::::::

Yellow Fever [to 18 February 2017]
http://www.who.int/emergencies/yellow-fever/en/
WHO: The yellow fever outbreak in Angola and Democratic Republic of the Congo ends
Brazzaville, 14 February 2017 – The Democratic Republic of Congo (DRC) declared the end of the yellow fever outbreak in that country today following a similar announcement in Angola on 23 December 2016, bringing an end to the outbreak in both countries after no new confirmed cases were reported from both countries for the past six months.

“We are able to declare the end of one of the largest and most challenging yellow fever outbreak in recent years through the strong and coordinated response by national authorities, local health workers and partners,” said Dr Matshidiso Moeti, the World Health Organization (WHO) Regional Director for Africa, commending the unprecedented and immense response to the outbreak.

The outbreak, which was first detected in Angola in December 2015, had caused 965 confirmed cases of yellow fever across the two countries, with thousands more cases suspected.  The last case detected in Angola was on 23 June 2016 and DRC’s last case was on 12 July the same year.

More than 30 million people were vaccinated in the two countries in emergency vaccination campaigns. This key part of the response included mop up and preventative campaigns in hard to reach areas up until the end of the year to ensure vaccine protection for as many people in all areas of risk as possible.  This unprecedented response exhausted the global stockpile of yellow fever vaccines several times.

More than 41,000 volunteers and 8,000 vaccination teams with more than 56 NGO partners were involved in the mass immunization campaigns. The vaccines used came from a global stockpile co-managed by Médecins Sans Frontières (MSF), International Federation of the Red Cross and Red Crescent Societies (IFRC), UNICEF and WHO. In the first 6 months of 2016 alone, the partners delivered more than 19 million doses of the vaccine – three times the 6 million doses usually put aside for an outbreak. Gavi, the Vaccine Alliance financed a significant proportion of the vaccines…

::::::

EBOLA/EVD [to 18 February 2017]
http://www.who.int/ebola/en/
No new digest content identified for this edition.

::::::

MERS-CoV [to 18 February 2017]
http://www.who.int/emergencies/mers-cov/en/
No new digest content identified for this edition.

 

WHO & Regional Offices [to 18 February 2017]

WHO & Regional Offices [to 18 February 2017]

Reducing maternal and newborn deaths by half
14 February 2017 – Today, 9 countries – Bangladesh, Cote d’Ivoire, Ethiopia, Ghana, India, Malawi, Nigeria, Tanzania and Uganda – committed to halving preventable deaths of pregnant women and newborns in their health facilities within the next 5 years. Through a new network supported by WHO, UNICEF, and other partners, these countries will improve the quality of care mothers and babies receive.

Highlights
Operationalising national plans on noncommunicable diseases prevention and control in Bhutan
Reducing harmful alcohol use, and improving diet and nutrition in Bhutan were among key areas focused on by the first joint mission to the country by the United Nations Interagency Task Force on the Prevention and Control of Noncommunicable diseases (NCDs).

Weekly Epidemiological Record, 17 February 2017, vol. 92, 7 (pp. 77–88)
:: Human rabies: 2016 updates and call for data

::::::

:: WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO and the African Union Commission map the way forward for stronger partnership
Brazzaville, 17 February 2017 – The World Health Organization (WHO) and the African Union Commission (AUC) held a bilateral meeting at the WHO Regional Office for Africa (WHO AFRO) Secretariat in Brazzaville on 16-17 February 2017 to take stock of progress in implementing their partnership agreement, discuss lessons learnt and map out the way forward. The meeting was attended by Senior Management from the African Union Commission, WHO AFRO and the WHO Regional Office for the Eastern and Mediterranean Region (WHO EMRO). Both organizations are undergoing reforms, and the meeting was an opportunity to synergize efforts around common goals such… read more
: WHO teams assist people in hard-to-reach areas of Nigeria – 17 February 2017
:: The yellow fever outbreak in Angola and Democratic Republic of the Congo ends – 14 February 201
[See Yellow Fever summary above for more detail]

WHO Region of the Americas PAHO
:: Cartoon Network, PAHO and UNICEF launch second phase of campaign to educate kids about preventing Zika (02/16/2017)

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: Cultural contexts of health project expands with grant to build better evidence base for Health 2020 17-02-2017
:: WHO’s commitment to air quality: from the 1950s to today 17-02-2017
:: New WHO/Europe report offers policy options to reduce out-of-pocket payments for medicines in Kyrgyzstan 15-02-2017
:: Expert meeting lays foundation for scaled-up action on strengthening public health services in Europe 15-02-2017

WHO Eastern Mediterranean Region EMRO
:: WHO responds to health needs of populations fleeing conflict in Al-Mokha City in Taizz governorate, Yemen
Sana’a, 12 February 2017 — As violent conflict continues in Al-Mokha City in Taizz governorate, Yemen, more than more than 8000 internally displaced persons have fled to several districts of Al-Hudaydah governorate. WHO teams in the governorate are providing trauma care and primary health care services to newly displaced persons, and delivering medicines and supplies to health facilities.

WHO Western Pacific Region
No new digest content identified.

CDC/ACIP [to 18 February 2017]

CDC/ACIP [to 18 February 2017]
http://www.cdc.gov/media/index.html
http://www.cdc.gov/vaccines/acip/

MMWR Weekly February 17, 2017 / No. 6
[Excerpts]
:: Update: Influenza Activity — United States, October 2, 2016–February 4, 2017
:: Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017
…This report uses data, as of February 4, 2017, from 3,144 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 28, 2016–February 4, 2017, to estimate an interim adjusted effectiveness of seasonal influenza vaccine for preventing laboratory-confirmed influenza virus infection associated with medically attended ARI. During this period, overall vaccine effectiveness (VE) (adjusted for study site, age group, sex, race/ethnicity, self-rated general health, and days from illness onset to enrollment) against influenza A and influenza B virus infection associated with medically attended ARI was 48% (95% confidence interval [CI] = 37%–57%). Most influenza infections were caused by A (H3N2) viruses. VE was estimated to be 43% (CI = 29%–54%) against illness caused by influenza A (H3N2) virus and 73% (CI = 54%–84%) against influenza B virus….
:: Transmission of Zika Virus — Haiti, October 12, 2015–September 10, 2016
:: Notes from the Field: Ongoing Cholera Epidemic — Tanzania, 2015–2016

Register for upcoming February ACIP meeting
February 22-23, 2017
Deadline for registration:
:: Non-US Citizens: February 1, 2017; US Citizens: February 13, 2017
Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Sabin Vaccine Institute [to 18 February 2017]

Sabin Vaccine Institute [to 18 February 2017]
http://www.sabin.org/updates/pressreleases
February 13, 2017
Sabin Vaccine Institute Names Deputy Assistant Secretary for Health as New President of Global Immunization
WASHINGTON, D.C.,– Sabin Vaccine Institute (Sabin), a non-profit dedicated to making life-improving vaccines more accessible, enabling innovation and expanding immunization across the globe, today announced the appointment of Dr. Bruce Gellin as President, Global Immunization. Dr. Gellin, a 15-year U.S. Department of Health and Human Services (HHS) veteran, has served as Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office since 2002. Among his roles, Dr. Gellin led discussions on behalf of the United States at high-level global and domestic policy advisory groups and was responsible for developing the National Vaccine Plan, our country’s blueprint for all aspects of vaccines and immunization.

Fondation Merieux [to 18 February 2017]

Fondation Merieux [to 18 February 2017]
http://www.fondation-merieux.org/news
Mission: Contribute to global health by strengthening local capacities of developing countries to reduce the impact of infectious diseases on vulnerable populations.
http://www.wellcome.ac.uk/news/drug-resistant-bugs-threaten-global-malaria-control

17 February 2017, Bamako (Mali)
From a Mobile Laboratory in Mali to a G5 Sahel Biosecurity Network
Plans are being made to create a biosecurity network covering the entire G5 Sahel area (Burkina Faso, Chad, Mali, Mauritania, and Niger), designed to deliver an improved response to biological threats, and more efficiently combat epidemics and the emergence of new categories of crises.
Financially backed by the GIZ (German Federal Enterprise for International Cooperation), the G5 Sahel project is mainly delivered on the ground by Fondation Mérieux and the Bundeswehr Institute of Microbiology in Munich, as part of the German Partnership Programme for Excellence in Biological and Health Security from the German Ministry of Foreign Affairs. The project is setting out to create a network of mobile laboratories in the G5 Sahel countries…

NIH [to 18 February 2017]

NIH [to 18 February 2017]
http://www.nih.gov/news-events/news-releases

Thursday, February 16, 2017
Investigational PfSPZ malaria vaccine demonstrates considerable protection in Malian adults for duration of malaria season
An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria — the deadliest form of the disease — for the duration of the malaria season, according to new findings published in the February 15th issue of the journal Lancet Infectious Diseases. The study participants live in Mali, Africa, where they are naturally exposed to the parasite.
The investigational vaccine, known as the PfSPZ Vaccine, contains live but weakened sporozoites, the form of the parasite that infects humans, and was developed by scientists at Sanaria Inc., of Rockville, Maryland. The study was conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the University of Science, Techniques, and Technologies of Bamako (USTTB), Mali, one of NIAID’s International Centers of Excellence in Malaria Research…

NIH research helps explain how antibody treatment led to sustained remission of HIV-like virus
February 15, 2017 — Research presents a new target for HIV prevention and treatment, and sheds light on how HIV develops.

UNAIDS [to 18 February 2017]

UNAIDS [to 18 February 2017]
http://www.unaids.org/
Update
HIV and gender inextricably linked
17 February 2017
The need to increase linkages between gender inequalities and HIV has been stressed as critical to advancing progress in health and across the Sustainable Development Goals (SDGs) at the launch of a new Centre for Gender and Global Health at University College London in the United Kingdom on 16 February.

Update
New HIV infections down by 18% in the United States of America
16 February 2017

EDCTP [to 18 February 2017]

EDCTP [to 18 February 2017]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
16 February 2017
PredART trial: prednisone reduces risk of TB-IRIS in HIV-infected patients by 30%
Results of the EDCTP-funded PredART clinical trial, led by Dr Graeme Meintjes, University of Cape Town, South Africa were presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) (Abstract #81LB) on 15 February 2017. The trial showed that prednisone, a cheap drug readily accessible in low- and middle-income countries, reduces the risk of developing TB-IRIS by 30% in patients on tuberculosis (TB) treatment starting antiretroviral therapy (ART). The trial also showed that prednisone is safe when used in patients with advanced HIV.
The findings of the PredART trial provide the first evidence of an effective strategy to reduce the risk of this very common complication of starting ART in HIV-infected patients undergoing TB treatment…
Read: Abstract ‘Randomized controlled trial of prednisone for prevention of paradoxical TB-IRIS’ presented a CROI 2017 on 15 February 2017.